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Background: Thrombosis remains a risk following all types of endovascular
intervention. Though considerable advances have been made in stent design, the design
factors leading to stent thrombosis—stent design, drug elution, and coatings—continue
to be improved and evaluated. It is critical that stents exhibit minimal surface
thrombogenicity to reduce the incidence of device-induced vessel thrombosis.
Methods: The left and right femoral artery of five domestic Yorkshire swine were
cannulated to create to an ex vivo blood shunt through polyethylene tubing with
silicone tubing sections to allow stent deployment before re-entry to the femoral vein.
3.0x18mm stents in the following groups were evaluated: bare metal stent (BMS, ML
VISION®), collagen coated BMS (BMS-c), XIENCE V® (XV), and Endeavor
Resolute (Res), and unstented silicone tubing (negative control). Six stents from each
group were inserted into the ex-vivo shunt system randomized in sequence. No
anticoagulation or antiplatelet agents were administered to the animals. Blood was
allowed to circulate through the shunt for 30 minutes, following which stents were
weighted for gravimetric assessment of thrombus burden and images were obtained.
Results: As expected, positive control collagen coated BMS exhibited the greatest
amount of thrombus, followed by BMS, then Endeavor Resolute. Xience V and
unstented silicone tubing had the least thrombus. The pre-stenting to post-stenting
weight differential of each was—BMS: 0.06±0.04, BMS-c: 0.10±0.02, Res:
0.021±0.003 (p<0.05 vs BMS, BMS-c), XV: 0.012±0.007 (p<0.05 vs BMS, BMS-c,
Res), Silicone tube: 0.010±0.011 (p<0.05 vs BMS, BMS-c, Res).
Conclusion: In a model of acute thrombogenicity, Xience V demonstrated the least
amount of thrombus in comparison to other second generation DES and BMS. This
preclinical thrombogenicity data appears to corroborate the low acute thrombosis rates
observed with Xience V in clinical practice.
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Background: Drug eluting stents (DES) have decreased the rate of in-stent restenosis
and been used as one of the most important devices for treatment of coronary artery
disease. Although most drugs inhibit mammalian target of rapamycin (mTOR), the
biological effects of DES toward stented vessels remain unknown. We examined
transcript expression by microarray analysis in stented blood vessels implanted with
two types of new generation DES, Nobori and Xience V.
Methods: One month after stent implantation in porcine coronary arteries, all animals
were euthanized and stented arteries were harvested for a microarray analysis. In this
study, total RNA from stented vessel segments (Nobori: n=4, Xience V: n=3) or non-
stented vessel segments (Control: n=2) were evaluated by using Agilent gene arrays.
Significant genes were selected with a cutoff of p<0.05 and fold change >2.
Results: 3,239 of 40,424 genes were considered differentially expressed and 533 genes
for Nobori and 1,503 genes for Xience V were exclusively altered in each group. In
pathway specific gene expression analysis, the expression levels of interleikin -1β
(2.13-fold, p<0.05), IL-2 receptor γ (2.70-fold, p<0.05), matrix metalloproteinase 9
(2.38-fold, p<0.05), monocyte chemoattractant protein-1 (2.17-fold, p<0.05), regulated
upon activation, normal T cell expressed and secreted (3.85-fold, p<0.05), chemokine
receptor 7 (5.56-fold, p<0.05), tissue necrotic factor (2.70-fold, p<0.05), selectin P
ligand (2.44-fold, p<0.05) and integrin β2 (2.38-fold, p<0.05) were decreased in Nobori
compared to Xience V. Interestingly, Adiponectin, C1q and collagen domain containing
(ADIPOQ) gene showed different expression in both group (2.77-fold increase
compared to Xience V, p=0.012) as well as fractalkine (C-X3-C motif ligand 1) gene
expressed (2.38-fold decrease compared to Xience V, p=0.048).
Conclusion: Based on this preliminary microarray gene expression study, expression
of inflammatory cytokines and adhesion molecules involved in inflammatory and
immune reactions were downregulated in Nobori stented blood vessesls compared to
Xience V.
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Background: Drug eluting stents (DES) have significantly improved restenosis rates.
However, some DES have been shown to inhibit wound healing and re-
endothelialization, leading to an increased risk of late stent thrombosis (LST).
Prolonged drug tissue concentration has been implicated as a potential source of
delayed healing. Although in vitro models can assess the dose and time-dependent
release kinetics of DES, in vivo models are needed to provide a more clinically relevant
environment for drug tissue content. The purpose of this study was to assess the tissue
drug concentrations of stented iliac rabbit arteries for four different DES on a head-to-
head basis.
Methods: Four DES were evaluated: Cypher (SES, sirolimus), Endeavor Sprint (ZES-
S, Zotarolimus), Endeavor Resolute (ZES-R, Zotarolimus), and XIENCE V® (EES,
Everolimus). Stents were implanted into both healthy rabbit iliac arteries for durations
of 3, 14, 28, 42, and 90 days. Arterial drug concentrations were measured with liquid
chromatography-mass spectrometry (LCMS).
Results: A model was created for tissue concentration based upon duration, treatment
group, and interaction effects (p<0.01, r2=0.51). Both treatment and duration were
significant effectors of tissue concentration (p<0.001). The drug tissue concentration
curve for ZES-S was significantly higher at 3 days. At 90 days, tissue drug
concentration for ZES-R was significantly higher than the other three devices (ng/mg):
EES: 0.38±0.37, ZES-S: 1.25±0.83, SES: 1.27±0.52, ZES-R: 3.53±1.27, p<0.001 ZES-
R vs EES, ZES-S, and SES. Surprisingly, at 90 days the drug tissue concentration for
ZES-S was numerically higher than for EES, but not significantly so.
Conclusion: In a healthy rabbit iliac artery, tissue drug concentration following stenting
was different between the different drug eluting stents as a function of time. Tissue
drug concentration was greatest at early time points with ZES-S and at late time points
with ZES-R. Differences in tissue drug concentration and duration of drug in tissue
may have implications for DES efficacy and inhibition of healing.
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Which Genes of the Nitric Oxide Pathway Contribute to Vascular Dysfunction
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Background: Histological studies have shown that pig coronary arteries become
endothelialized within 30 days after the implantation of drug eluting stent (DES).
However, quantitative angiographic assessment shows vasoconstriction in response to
acetylcholine challenge, indicating abnormal endothelial function. The present study
was aimed to understand the molecular mechanism of endothelial dysfunction in DES
implanted vessels.
Methods: Either bare metal or drug eluting stents with different polymers or drug were
implanted in farm pigs in a total of 16 vessels. After 30 days, in vivo vascular function
was assessed by acetylcholine challenge test. Vessels were harvested for histology,
quantitative RT-PCR and western blot analysis. Specific analysis of nitric oxide
pathway genes was performed.
Results: In vivo quantitative angiography confirmed vasoconstriction and vasodilation
indicating the presence of endothelial dysfunction in DES implanted arteries. Real-
Time PCR showed a major upregulation of two of the NOS pathway genes, Arginase
(100-3000 fold) and DDAH (5-7 fold). Only a small but significant (2 fold) change in
eNOS gene expression was also observed. The gene expression changes were localized
in the intima and media as the majority of the tissue used was derived from the intima
and media. Histological evaluation showed higher angiogenesis in DES implanted
vessels as compared to the BMS implanted arteries. Our results suggest that increase
in eNOS gene expression may be related to the angiogenic response whereas high
arginase expression may deplete the substrate for NO generation and thereby contribute
to endothelial dysfunction. An increased expression of DDAH is expected to be
beneficial by reducing ADMA and superoxide generation.
Conclusion: Gene expression studies have provided new insight into the role of nitric
oxide pathway genes in vascular response and endothelial dysfunction observed in
DES implanted pig arteries. Our studies for the first time show that arginase and DDAH
may be important players in modulating vascular response in DES implanted coronary
arteries.
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Background: Though drug eluting stents (DES) have significantly improved restenosis
rates, some (DES) have been shown to inhibit re-endothelialization, leading to an
increased risk of late stent thrombosis. An optimal DES design would deliver sufficient
drug to inhibit restenosis but have minimal impact on healing. Most pharmacokinetic
(PK) studies have been performed in healthy animals and the relevance of this patients
with atherosclerotic disease remains an open question. The purpose of this study was
to assess the tissue drug concentrations achieved with several DES in both healthy and
atherosclerotic rabbit iliac arteries.
Methods: Four DES were evaluated: Cypher (SES, Sirolimus), Endeavor Sprint (ZES,
Zotarolimus), Taxus Liberte (PES, Paclitaxel), and XIENCE V® (EES, Everolimus).
Stents were implanted into healthy and atherosclerotic rabbit iliac arteries for durations
up to 90 days. Arterial drug concentrations were measured with liquid chromatography-
mass spectrometry and compared between devices and models.
Results: A multivariant model is being assembled to determine the dependency on
model type, treatment type and duration. At all time points and for all types of DES,
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